Developing a Sourcing Strategy at Medwell Pharmaceutical Corporation
GBUS 450 Case Study 3:
Developing a Sourcing Strategy at
Medwell Pharmaceutical Corporation
Case Background
Medwell Pharmaceutical Corporation (MPC), Inc. is a medium-sized (but growing) pharmaceutical company located in central New Jersey. The company’s new drugRegenerix has recently been approved for commercialization by FDA. MPC knows it must manage its product launch quickly and effectively, in order to occupy the market.
As a result of an earlier study conducted by corporate personnel and an external consultant, executive management has decided they outsource the production of various intermediaries. Executive management believes this will save investment dollars as well as time. It will also allow MPC to focus its efforts and investments in areas that the company feels most closely align with its core capabilities. This case focuses on the sourcing of a major intermediary code named Intermediary 331 by the product design team.
It is currently April 2012. MPC plans for pilot production and ramp up to begin in early November with the introduction of Regenerix in the U.S. in January 2013. The product will be introduced to other countries as the company receives approval from the appropriate regulatory authorities. The team decided to visit three suppliers to collect detailed information and interview managers. Summarize data were collected during the commodity team's visits to each supplier.
At MPC's point of view, we audit and estimate potential suppliers. Based on a complete analysis, including financial risk analysis, total cost analysis and supplier evaluation and selection analysis, we will propose recommended selection, discussion of the type of contract to pursue, key negotiation issues. After sourcing risk analysis, we will also offer risk management plan and a timeline to implement the sourcing strategy.
Identification of the selected suppliers
Developing a Sourcing Strategy at
Medwell Pharmaceutical Corporation
Case Background
Medwell Pharmaceutical Corporation (MPC), Inc. is a medium-sized (but growing) pharmaceutical company located in central New Jersey. The company’s new drugRegenerix has recently been approved for commercialization by FDA. MPC knows it must manage its product launch quickly and effectively, in order to occupy the market.
As a result of an earlier study conducted by corporate personnel and an external consultant, executive management has decided they outsource the production of various intermediaries. Executive management believes this will save investment dollars as well as time. It will also allow MPC to focus its efforts and investments in areas that the company feels most closely align with its core capabilities. This case focuses on the sourcing of a major intermediary code named Intermediary 331 by the product design team.
It is currently April 2012. MPC plans for pilot production and ramp up to begin in early November with the introduction of Regenerix in the U.S. in January 2013. The product will be introduced to other countries as the company receives approval from the appropriate regulatory authorities. The team decided to visit three suppliers to collect detailed information and interview managers. Summarize data were collected during the commodity team's visits to each supplier.
At MPC's point of view, we audit and estimate potential suppliers. Based on a complete analysis, including financial risk analysis, total cost analysis and supplier evaluation and selection analysis, we will propose recommended selection, discussion of the type of contract to pursue, key negotiation issues. After sourcing risk analysis, we will also offer risk management plan and a timeline to implement the sourcing strategy.
Identification of the selected suppliers